OM:SOBIBiotechs
How Does Sobi Stack Up After Its 14.5% Slide and Recent FDA Approval?
If you are wondering what to do with your Swedish Orphan Biovitrum shares, or considering adding them to your watchlist, you are not alone. The stock has sparked plenty of conversation among investors, especially after a rollercoaster 12 months. Year-to-date, the share price is down 14.5%, and it has slipped 13.6% over the past year. Short-term traders saw some mild volatility too, with a dip of 2.5% in the past week serving as a reality check after a 1.2% bump over the last month.
However,...
